Press coverage about Palatin Technologies (NYSE:PTN) has been trending positive recently, according to AlphaOne. The research group, a division of Accern, ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Palatin Technologies earned a news impact score of 0.46 on AlphaOne’s scale. AlphaOne also gave media stories about the biopharmaceutical company an impact score of 95 out of 100, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the next few days.

Insider Buying and Selling by Quarter for Palatin Technologies (NYSE:PTN)

Separately, Canaccord Genuity set a $6.00 target price on shares of Palatin Technologies and gave the company a “buy” rating in a research note on Tuesday, May 16th.

Shares of Palatin Technologies (NYSE:PTN) traded up 0.0272% during midday trading on Tuesday, reaching $0.3675. 939,191 shares of the company’s stock were exchanged. The firm’s market cap is $56.15 million. The stock’s 50-day moving average is $0.39 and its 200 day moving average is $0.41. Palatin Technologies has a one year low of $0.29 and a one year high of $0.90.

Palatin Technologies (NYSE:PTN) last posted its quarterly earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.10 by $0.12. The business had revenue of $10.82 million for the quarter, compared to analyst estimates of $60 million. During the same period in the prior year, the company posted ($0.01) earnings per share. Analysts anticipate that Palatin Technologies will post ($0.06) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at

Palatin Technologies Company Profile

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with's FREE daily email newsletter.